Cryo-Cell International (FRA:ZCY) Shares Outstanding (EOP): 8.06 Mil (As of Feb. 2026)


FRA:ZCY Cryo-Cell International Inc FRA:ZCY
63 GF Score
Price €2.86
GF Value €4.50
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Cryo-Cell International Shares Outstanding (EOP)?

Cryo-Cell International FRA:ZCY +2.88% 63 Shares Outstanding (EOP) is 8.06 Mil as of Feb. 2026. GuruFocus rates FRA:ZCY with a GF Score™ of 63/100 and a GF Value™ of €4.50 (Possible Value Trap). The stock has 4 warning signs investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Cryo-Cell International's shares outstanding for the quarter that ended in Feb. 2026 was 8.06 Mil.

Cryo-Cell International's quarterly shares outstanding stayed the same from Nov. 2025 (8.06 Mil) to Feb. 2026 (8.06 Mil).

Cryo-Cell International's annual shares outstanding declined from Nov. 2024 (8.08 Mil) to Nov. 2025 (8.06 Mil). It means Cryo-Cell International bought back shares from Nov. 2024 to Nov. 2025 .


Cryo-Cell International  (FRA:ZCY) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Cryo-Cell International Shares Outstanding (EOP) Related Terms


Cryo-Cell International Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Cryo-Cell International's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cryo-Cell International Shares Outstanding (EOP) Chart

Cryo-Cell International Annual Data
Trend Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23 Nov24 Nov25
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.56 8.50 8.29 8.08 8.06

Cryo-Cell International Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.08 8.06 8.06 8.06 8.06

FRA:ZCY vs CCM, CDIX, EHSI: Shares Outstanding (EOP) Comparison

For the Medical Care Facilities subindustry, Cryo-Cell International's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cryo-Cell International Shares Outstanding (EOP) vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Cryo-Cell International's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Cryo-Cell International's Shares Outstanding (EOP) falls into.


FRA:ZCY
63GF Score
Cryo-Cell International Inc FRA:ZCY
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cryo-Cell International Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 8.06 Mil mean?
Cryo-Cell International (FRA:ZCY) has a Shares Outstanding (EOP) of 8.06 Mil as of Feb. 2026. The total shares a company has outstanding, at period-end. View historical data on Cryo-Cell International and its competitors.
Is Cryo-Cell International's Shares Outstanding (EOP) too high?
Cryo-Cell International's current Shares Outstanding (EOP) is 8.06 Mil. Overall, Cryo-Cell International has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cryo-Cell International's Shares Outstanding (EOP) compare to CCM and CDIX?
Cryo-Cell International's Shares Outstanding (EOP) of 8.06 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Healthcare Providers & Services company?
A good Shares Outstanding (EOP) depends on the Healthcare Providers & Services industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Cryo-Cell International and its competitors. Cryo-Cell International's current Shares Outstanding (EOP) is 8.06 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cryo-Cell International stock overvalued right now?
Based on GuruFocus' analysis, Cryo-Cell International (FRA:ZCY) is currently considered Possible Value Trap. The stock's GF Value™ is €4.50, compared to a current price of €2.86 — trading 36.4% below its estimated fair value. The current Shares Outstanding (EOP) is 8.06 Mil. Cryo-Cell International's overall GF Score™ is 63/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Cryo-Cell International (FRA:ZCY), the current Shares Outstanding (EOP) is 8.06 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cryo-Cell International (FRA:ZCY) Overvalued in 2026?

Based on GuruFocus' analysis, Cryo-Cell International stock appears to be undervalued. The current stock price of €2.86 is trading 36.4% below its estimated GF Value™ of €4.50. GuruFocus considers Cryo-Cell International to be Possible Value Trap.

Key valuation signals for FRA:ZCY:

  • Shares Outstanding (EOP): 8.06 Mil
  • GF Value™: €4.50 vs. price of €2.86 (36.4% below fair value)
  • GF Score™: 63/100 with 4 warning signs

No single metric tells the full story. See the FRA:ZCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cryo-Cell International Business Description

Other Exchanges CCEL:USA
Address 700 Brooker Creek Boulevard, Suite 1800, Oldsmar, FL, USA, 34677
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
63GF Score

Get the complete analysis for FRA:ZCY

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.86
Price
€4.50
GF Value